Cobimetinib for BRAF-wild-type or Mutated Histiocytoses

Summary

COBRAH is a randomized double-blind 2-steps controlled superiority trial, with 2 parallel groups. Patients will be randomly assigned in a 2:1 ratio to receive Cobimetinib orally or placebo during the first 12-weeks step, allowing the determination of the primary criteria.

Timeline

Start

2019-07-25

Primary completion

2021-10-05

Completion

2022-03-14

Drugs

Indications